AP1646A

Flow resistance modulated aerosolized active agent delivery.

Abstract

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be admixture with a propellant. The active agent formulation is delivered to a patient at a low inspiratory flow rate for an initial period of time to increase bioavailability of the active agent.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

Every citation, both ways

Citations
DocumentRelationOfficeCited during
EP0808635A2CitesEuropean Patent Office (EPO)Search report
US4592348ACitesUnited States of AmericaSearch report
US5027806ACitesUnited States of AmericaSearch report
US5692496ACitesUnited States of AmericaSearch report